Zurich, 21 September 2022 – Mirabaud Advisors has acted as exclusive advisor to Swiss pharmaceutical innovator Scailyte in a CHF 6 million Series A fund raise from various investors
Views of our experts
The half-year numbers of Swiss Industrials, reported in July or August, were good, mostly unaffected by the rapid price increase of raw materials. Pricing power was strong, and in an environment with solid economy data, companies were able to respond quickly to the cost pressure. Arguably, there were some exceptions: Bystronic, Daetwyler, Forbo and Schweiter, which warned before and/or missed market consensus.